News sentiment analysis powered by sentiment-insight.com
Activist Icahn sues Illumina board over Grail acquisition - FT
Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing company Grail.
Carl Icahn sues Illumina board for violating 'fiduciary duties' Icahn said the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. Illumina repurchased Grail in 2021 despite opposition from U.S. and European antitrust regulators.
Carl Icahn sues Illumina board for violating 'fiduciary... Icahn said the lawsuit pertained to Illumina completing its acquisition of cancer detection test maker Grail. Illumina said it is reviewing the complaint, while Icahn and Grail did not immediately respond to Reuters requests for a comment.
Illumina to divest Grail within a year if it does not... Illumina to divest Grail within a year if it does not win challenge in EU court. Illumina is required to continue to fund Grail until it divests it.
EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail. The EU said Illumina closed the deal without approval of regulators in the 27-nation bloc.
Illumina ordered by EU antitrust regulators to sell Grail U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail. Antitrust watchdogs on both sides of the Atlantic have sharpened their scrutiny of pharma and biotech deals in recent years.
Illumina ordered by EU antitrust regulators to sell Grail U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail. The company completed the deal before securing their approval.
Illumina to divest cancer test maker Grail if it loses US or EU court appeal Illumina Inc said it will divest cancer test maker Grail as expeditiously as possible if it loses either of the final appeals in U.S. or European courts. The company also said that if it wins both the cases, it will reassess Grail's assets.
Illumina to divest Grail if it loses final court... Illumina to divest Grail if it loses final court appeals in US or EU. Illumina completed its $7.1 billion takeover of Grail in August 2021.
UPDATE 1-Illumina to divest Grail if it loses final court appeals in US or EU Illumina will divest cancer test maker Grail if it loses final appeals in U.S. or European courts. Smithfield Foods Inc. will close a North Carolina pork plant. Exxon Mobil agreed to buy Pioneer Natural Resources Co. for $59.5 billion.
Illumina to get EU order on Thursday to divest Grail, source says U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cancer test maker Grail. A year after the $7.1 billion deal was blocked, a person with direct knowledge of the matter said.
Illumina to get EU order on Thursday to divest Grail, source says U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cancer test maker Grail. The EU competition enforcer slapped a record 432 million-euro fine on Illumina in July for closing the deal before securing regulatory green light.
Illumina to get EU order on Thursday to divest Grail,... U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cancer test maker Grail. The EU competition enforcer slapped a record 432 million-euro ($458 million) fine on Illumina in July for closing the deal before securing regulatory green light.
EU regulatory order for Illumina to sell Grail could come next week - FT EU competition regulators could order Illumina to sell cancer detection test maker Grail. The U.S. life sciences company had completed its $7.1 billion takeover of Grail in August 2021. The genetic testing company was fined a record 432 million euros ($476 million) by the EU earlier this year.
EU regulatory order for Illumina to sell Grail could... EU order for Illumina to sell Grail could come as early as next week, FT reports. U.S. life sciences company completed its $7.1 billion takeover of Grail in August 2021. Illumina was fined a record 432 million euros ($476 million) by the EU earlier this year.
Carl Icahn says new Illumina CEO has his 'full support' months after proxy fight Carl Icahn expressed his support for Illumina's new CEO Jacob Thaysen. "I think he will do an excellent job and he has my full support," Icahn said. Icahn launched a proxy battle over the company's $7.1 billion acquisition of cancer test developer Grail.
Reuters Health News Summary U.S. Securities and Exchange Commission (SEC) has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail. China's northern region of Inner Mongolia reports two cases of bubonic plague. Namibia bans poultry imports from Denmark, Netherlands due to bird flu.
US securities regulator probes Illumina over Grail deal The U.S. Securities and Exchange Commission has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail. The regulator requested documents and communications related to the acquisition.
SEC investigating Illumina over acquisition of cancer test developer Grail The Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail. Illumina, in the filing, said it is cooperating with the SEC. Shares of Illumina fell about 4% on Friday.
European Union fines biotech giant Illumina $475 million for taking over cancer-screening company Grail without approval European Union fines biotech giant Illumina $475 million for taking over cancer-screening company Grail. 26-year-old woman dies after falling 500 feet at Rocky Mountain National Park.
Sign Up